Amphastar Pharmaceuticals

Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company.[2] It was incorporated in May 2004 and primarily develops, manufactures and sells inhalation and intranasal products.[3]

Amphstar Pharmaceuticals, Inc.
TypePublic
HeadquartersRancho Cucamonga, California, United States
Key people
  • Mary Z. Luo
  • (Chairman of the Board)
  • Jack Yongfeng Zhang
  • (CEO)
Revenue US$ 240.18 million (2017)
US$ -895 thousand (2017)
US$ -4.51 million (2017)
Total assets US$ 454.67 million (2017)
Total equity US$ 337.33 million (2017)
Number of employees
~2000
WebsiteAmphastar.com
Footnotes / references
[1]

One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic.[4] In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally.[4]

In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case.[5]

References


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.